Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F21%3A00081478" target="_blank" >RIV/00023001:_____/21:00081478 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/21:N0000069 RIV/00064203:_____/21:10430319 RIV/00216208:11130/21:10430319
Result on the web
<a href="https://www.mdpi.com/2227-9059/9/8/1053/htm" target="_blank" >https://www.mdpi.com/2227-9059/9/8/1053/htm</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/biomedicines9081053" target="_blank" >10.3390/biomedicines9081053</a>
Alternative languages
Result language
angličtina
Original language name
Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation
Original language description
This study evaluates the effects of chronic treatment with EET-A, an orally active epoxyeicosatrienoic acid (EETs) analog, on the course of aorto-caval fistula (ACF)-induced heart failure (HF) in Ren-2 transgenic rats (TGR), a model characterized by hypertension and augmented activity of the renin-angiotensin system (RAS). The results were compared with standard pharmacological blockade of the RAS using angiotensin-converting enzyme inhibitor (ACEi). The rationale for employing EET-A as a new treatment approach is based on our findings that apart from increased RAS activity, untreated ACF TGR also shows kidney and left ventricle (LV) tissue deficiency of EETs. Untreated ACF TGR began to die 17 days after creating ACF and were all dead by day 84. The treatment with EET-A alone or ACEi alone improved the survival rate: in 156 days after ACF creation, it was 45.5% and 59.4%, respectively. The combined treatment with EET-A and ACEi appeared to improve the final survival to 71%; however, the difference from either single treatment regimen did not reach significance. Nevertheless, our findings support the notion that targeting the cytochrome P-450-dependent epoxygenase pathway of arachidonic acid metabolism should be considered for the treatment of HF.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/NV17-28220A" target="_blank" >NV17-28220A: Pharmacological targeting of cytochrome P-450-derived metabolites of arachidonic as a new approach to treatment of congestive heart failure</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedicines
ISSN
2227-9059
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
8
Country of publishing house
CH - SWITZERLAND
Number of pages
28
Pages from-to
"art. no. 1053"
UT code for WoS article
000688874400001
EID of the result in the Scopus database
2-s2.0-85113666016